Table 1.
Characteristics of eligible studies
| Author, year | Country | Study design | Inclusion Period | Neoadjuvant CT | Type of neoadjuvant/adjuvant CT | Total number of patients | Number of patients according to ER status | % CT and HT as adjuvant |
|---|---|---|---|---|---|---|---|---|
| Balduzzi, 2012 | Italy | Retrospective analysis of prospectively collected data | 1995-2009 | No | Anthracycline only, anthracycline and CMF, taxane only, CMF only, others | 1424 | <1%: 1300 1%-10%: 124 |
HT 5; CT 89 HT 41; CT 59 |
| Colleoni, 2004 | Italy | Retrospective analysis of prospectively collected data | 1994-2002 | Yes | Anthracycline Anthracycline and taxane Other |
399 | <1%: 129 1%-9%: 94 ≥10%: 171 |
NR |
| Dieci, 2021 | Italy | Retrospective | 2000-2019 | Yes (41% of study cohort) | Anthracyclines and/or taxanes Other |
406 | <1%: 364 1%-9%: 42 |
HT 4; CT 100 HT 14; CT 100 |
| Ding, 2019 | China | Retrospective | 2007-2017 | Yes | Anthracycline, cyclophosphamide, and paclitaxel sequentially or concomitant | 570 | <1%: 209 1%-10%: 60 >10%: 301 |
NR |
| Fujii, 2017 | USA | Retrospective | 1982-2013 | Yes | Anthracyclines alone Taxanes alone Anthracycline and taxane |
3055 | <1%: 932 1%-9%: 171 ≥10%: 1952 |
HT 9; CT 17 HT 25; CT 9 HT 98; CT 15 |
| Landmann, 2018 | USA | Retrospective | 2010-2014 | Yes | Adriamycin-cyclophosphamide-taxane Other/unknown |
327 | <1%: 141 1%-10%: 41 >10%: 145 |
NR |
| Ohara, 2019 | Japan | Retrospective | 2004-2013 | Yes | Paclitaxel, followed by FEC | 156 | <1%: 32 1%-9%: 16 ≥10%: 108 |
NR |
| Prabhu, 2014 | India | Prospective | 2008-2013 | No | Anthracycline and taxane Anthracycline plus other Other |
235 | <1%: 74 1%-10%: 21 >10%: 140 |
HT 0; CT 84 HT 71; CT 76 HT 91; CT 59 |
| Raghav, 2012 | USA | Retrospective | 1990-2009 | No | Anthracycline-based, taxane-based, anthracycline and taxane, other | 1257 | <1%: 897 1%-5%: 241 6%-10%: 119 |
HT 4; CT 74 HT 14; CT 70 HT 40; CT 72 |
| Villegas, 2021 | Germany | Post hoc analysis of randomized data | NR | Yes | Anthacycline- and taxane-based | 2765 | <1%: 902 1%-9%: 94 ≥10%: 1769 |
NR |
| Yi, 2014 | USA | Retrospective | 1990-2011 | Yes (no separate data) | NR | 9639 | <1%: 1625 1%-9%: 250 ≥10%: 7764 |
HT 12.9; CT 49.7 HT 20.4; CT 49.2 HT 83.6; CT 35.5 |
| Zhang, 2014 | USA | Retrospective | 2000-2011 | No | NR | 1700 | <1%: 401 1%-10%: 32 >10%: 1267 |
HT 11; CT 78 HT 87; CT 81 HT 99; CT 86 |
CMF, cyclophosphamide, methotrexate, fluorouracil; CT, chemotherapy; ER, estrogen receptor; ET, endocrine therapy; FEC, fluorouracil, epirubicin, cyclophosphamide; HT, hormone therapy; NR, not reported.